company background image
JNCE

Jounce Therapeutics NasdaqGS:JNCE Stock Report

Last Price

US$4.79

Market Cap

US$247.6m

7D

-0.6%

1Y

-8.9%

Updated

16 Aug, 2022

Data

Company Financials +
JNCE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

JNCE Stock Overview

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.

Jounce Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jounce Therapeutics
Historical stock prices
Current Share PriceUS$4.79
52 Week HighUS$9.81
52 Week LowUS$2.76
Beta1.17
1 Month Change40.06%
3 Month Change4.13%
1 Year Change-8.94%
3 Year Change28.76%
5 Year Change-68.02%
Change since IPO-72.23%

Recent News & Updates

Jun 16
Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation

Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

JNCEUS BiotechsUS Market
7D-0.6%1.4%3.6%
1Y-8.9%-19.6%-9.6%

Return vs Industry: JNCE exceeded the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: JNCE matched the US Market which returned -9.6% over the past year.

Price Volatility

Is JNCE's price volatile compared to industry and market?
JNCE volatility
JNCE Average Weekly Movement12.2%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: JNCE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: JNCE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012137Rich Murrayhttps://jouncetx.com

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment.

Jounce Therapeutics Fundamentals Summary

How do Jounce Therapeutics's earnings and revenue compare to its market cap?
JNCE fundamental statistics
Market CapUS$247.62m
Earnings (TTM)-US$131.21m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
JNCE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$54.98m
Gross Profit-US$54.97m
Other ExpensesUS$76.23m
Earnings-US$131.21m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.54
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did JNCE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is JNCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JNCE?

Other financial metrics that can be useful for relative valuation.

JNCE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does JNCE's PB Ratio compare to its peers?

JNCE PB Ratio vs Peers
The above table shows the PB ratio for JNCE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.5x
VSTM Verastem
4.8x60.5%US$257.3m
CMRX Chimerix
8.4x-38.7%US$234.8m
NXTC NextCure
0.7x3.9%US$142.1m
VYGR Voyager Therapeutics
3.9x-9.5%US$235.0m
JNCE Jounce Therapeutics
1.6x8.8%US$247.6m

Price-To-Book vs Peers: JNCE is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (4.5x).


Price to Earnings Ratio vs Industry

How does JNCE's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: JNCE is good value based on its Price-To-Book Ratio (1.6x) compared to the US Biotechs industry average (2x)


Price to Book Ratio vs Fair Ratio

What is JNCE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JNCE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate JNCE's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of JNCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate JNCE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate JNCE's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Jounce Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: JNCE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: JNCE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: JNCE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: JNCE's revenue (52.1% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: JNCE's revenue (52.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if JNCE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Jounce Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-33.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: JNCE is currently unprofitable.

Growing Profit Margin: JNCE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: JNCE is unprofitable, and losses have increased over the past 5 years at a rate of 33.3% per year.

Accelerating Growth: Unable to compare JNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: JNCE has a negative Return on Equity (-83.18%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Jounce Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: JNCE's short term assets ($157.3M) exceed its short term liabilities ($23.2M).

Long Term Liabilities: JNCE's short term assets ($157.3M) exceed its long term liabilities ($8.0M).


Debt to Equity History and Analysis

Debt Level: JNCE is debt free.

Reducing Debt: JNCE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: JNCE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: JNCE has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 30.7% each year.


Discover healthy companies

Dividend

What is Jounce Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate JNCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate JNCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if JNCE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if JNCE's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as JNCE has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.5yrs

Average management tenure


CEO

Rich Murray (63 yo)

8.08yrs

Tenure

US$3,236,167

Compensation

Dr. Richard Murray, also known as Rich, Ph D., has been the Chief Executive Officer, President and Director of Jounce Therapeutics, Inc., since July 10, 2014. Prior to joining Jounce, Dr. Murray serves as...


CEO Compensation Analysis

Compensation vs Market: Rich's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: JNCE's management team is seasoned and experienced (9.5 years average tenure).


Board Members

Experienced Board: JNCE's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Jounce Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Jounce Therapeutics, Inc.
  • Ticker: JNCE
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$247.615m
  • Shares outstanding: 51.69m
  • Website: https://jouncetx.com

Number of Employees


Location

  • Jounce Therapeutics, Inc.
  • 780 Memorial Drive
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.